论文部分内容阅读
目的:探讨MMP-26和MMP-7在非小细胞肺癌(NSCLC)中的表达情况及其与其临床病理特征的关系。方法:采用免疫组化的方法对70例NSCLC组织和30例癌旁正常肺组织进行MMP-26和MMP-7表达分析。结果:①肿瘤细胞MMP-26阳性表达率为64.3%;鳞癌、腺癌和大细胞癌组MMP-26表达水平依次降低(P<0.05);随着肿瘤分化程度降低和TNM分期增加MMP-26表达水平下降(P<0.01);②肿瘤细胞MMP-7阳性表达率为57.1%;腺癌MMP-7表达率高于其它组织学类型(P<0.05);MMP-7表达水平与TNM分期有关,且分期越高,表达率越高(P<0.05)。结论:MMP-26表达缺失意味着肿瘤恶性程度高,MMP-7表达增高则提示肿瘤侵袭能力增强。同时检测二者有助于判断NSCLC的恶性程度和预后。
Objective: To investigate the expression of MMP-26 and MMP-7 in non-small cell lung cancer (NSCLC) and its relationship with clinicopathological features. Methods: The expression of MMP-26 and MMP-7 in 70 NSCLC tissues and 30 adjacent normal lung tissues were detected by immunohistochemistry. Results: ① The positive rate of MMP-26 in tumor cells was 64.3%. The expression of MMP-26 in squamous cell carcinoma, adenocarcinoma and large cell carcinoma decreased in turn (P <0.05). With the decrease of tumor differentiation and the increase of MMP- 26 (P <0.01); ② The positive rate of MMP-7 in tumor cells was 57.1%; the expression of MMP-7 in adenocarcinoma was higher than that in other histological types (P <0.05) Related, and the higher the staging, the higher the expression rate (P <0.05). Conclusion: The lack of expression of MMP-26 means that the malignant degree of tumor is high. The increased expression of MMP-7 suggests that the invasion ability of tumor is enhanced. Simultaneous detection of both can help determine the degree of malignancy and prognosis of NSCLC.